Bone marrow biopsies are not a routinely recommended part of the work up and diagnosis of ITP in accordance to multiple international guidelines, but a new study re-examines this approach.

The failure of a third of individuals with chronic ITP to respond to aggressive immunosuppressive therapy or splenectomy has raised the suspicion that other molecular mechanisms may contribute to ...

Stimulating platelet production with romiplostim is an effective strategy for managing patients with ITP. Thrombocytopenias can be caused by increased platelet destruction, decreased platelet ...

Progress in understanding the origins, diagnosis, and treatment of immune thrombocytopenia (ITP) has been frustratingly slow for decades, in part because of the heterogeneous nature of the disorder.

Further information The NICE-Wide Prioritisation Board and NHS England have agreed that a Technology Appraisal (TA) would not be appropriate for this product and recommended that it is not selected ...

Sanofi has reported that the Phase III LUNA 3 trial of rilzabrutinib for the treatment of persistent or chronic immune thrombocytopenia (ITP) in the adult population, met its primary endpoint.

The first patient has been enrolled in a Phase 1 trial by the NHLBI that's evaluating fostamatinib as a treatment for sickle ...

In ITP, no anti-FcRn therapeutic has yet been approved ... protease CYR212 has been selected as its clinical candidate for chronic IgG-driven autoimmune diseases.